Kornimate/medical-research-clean huggingface dataset:
characterization phenotypic and genetic study of the intestinal epithelial dysplasia or tufting enteropathy (te)

Conditions: Intestinal Epithelial Dysplasia; Tufting Enteropathy

Summary: this phrc is centred on the intestinal epithelial dysplasia ( dei) or " tufting enteropathy " or te the clinical and histo-pathological descriptions of which are specified well to the digestive plan(shot).

the objectives of this phrc are: * the phenotypic analysis of the intestinal epithelial dysplasia by clinical and histo-pathological investigations. * the identification of proteins involved at the intestinal level in the differentiation, the proliferation and the membership of the epithelial cells * from the phenotypic study, a genetic analysis of type maps by homozygote on the whole genome partner in an approach guided by possible candidate genes * the study of the genes, chosen according to their location, to their profile of expression, and to their function in touch with the pathogenic hypotheses

Eligibility criteria:
inclusion criteria : patient sent in the service of gastroenterology pediatric hepatology of the hospital necker enfants malades for an intestinal transplantation, from 0 to 15 years old presenting: * a known epithelial dysplasia (diagnosis established on the clinical and histo-morphological criteria from one or several intestinal biopsies, with or without diagnosis known or suspected in the family). the objectives are the phenotypic characterization of the case and the revealing of markers characteristic immuno-histochemistry which can be of use to the diagnosis and direct to candidate genes * or a suspicion of dysplasia epithelial (compatible clinical history(story) with or without extra-digestive demonstrations(appearances) of type keratinate punctuated superficial (kps), abnormalities cutanea or atresia choans with atypical digestive histology and without diagnosis known in the family). the objectives are the diagnosis on the basis of the immuno-histochemistry expression and the existence of an infringement(achievement) conjunctival and the phenotypic characterization of the case * the lit(enlightened) and written consent of both holders of the parental authority must be beforehand obtained as well as that of the patient if it is in age to understand(include). exclusion criteria : * not membership in a national insurance scheme (beneficiary or legal successor) * family not understanding(including) french * refusal of one of both relatives(parents)

Keywords: intestinal epithelial dysplasia characterization phenotypic genetic study or " tufting enteropathy "
multi-center study safety of adipose derived mesenchymal stem cells for the treatment of multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the intent of this clinical study is to answer the questions: 1) is the proposed treatment safe and 2) is treatment effective in improving the disease pathology of patients with multiple sclerosis and clinical outcomes.

this will be an open-label, non-randomized multi-center patient sponsored study of adsc implantation using an iv delivery system. the study will provide therapies to up to 100 qualified patients who match the inclusion/exclusion criteria, agree to the follow up program and who have provided a signed consent for each procedure. the treatment is a combination of (a) general detoxification, (b) lymphatic massage/drainage, (c) therapeutic massage, reflexology and acupuncture and (d) cellular infusion therapy in which cells will be deployed via iv injection over two treatments of 60 minutes each during the five (5) day treatment period. follow-up data based upon msis-29, a modified sf-36 and standard complication questionnaire will be collected at 3, 6 and then annually post treatment by the patients' local physician and reported back to the sponsor where it will be logged into a hippa-compliant outcomes database. additional safety data, based upon a standard complication questionnaire will be collected via survey of patient at intervals of 3 and 6 months and then annually for a minimum of five (5) years.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of ms * aged 18 - 65 years. * duration of disease: \>5 years * signed, written informed consent willing and able to comply with study visits according to protocol for the full study period * physically, mentally and legally capable of international travel for treatment exclusion criteria: * patients suffering from significant cardiac, renal or hepatic failure or any other disease that may risk the patient or interfere with the ability to interpret the results * patient with any active or chronic infection * no life-threatening organ dysfunction. * pregnancy or risk of pregnancy. * severe physical limitations or disabilities * patients who are seropositive for hiv1, hiv2, hepatitis b surface antigen, and hepatitis c * patients unable to give written informed consent in accordance with research ethics board guidelines * treatment with any immunosuppressive therapy within the 3 months prior to randomization * current treatment with an investigational therapy

Keywords: ms multiple sclerosis, relapsing-remitting multiple sclerosis, chronic progressive myelitis
evaluation of accuvein in cirrhotics patients

Conditions: Liver Cirrhosis

Summary: the objective of this study is to evaluate the effectiveness of accuvein av400 to facilitate placement of peripheral intravenous catheters in cirrhotic adults by comparing the success rate of the first attempt to install a peripheral venous catheter with or without accuvein av400®.


Eligibility criteria:
inclusion criteria: * patient older than 18 years old * patient presenting a liver cirrhosis * patient requiring the placement of a venous peripheral catheter * patient informed and giving free and informed consent * patient affiliated to a french social security scheme exclusion criteria: * patient under 18 years old * patient unable to give consent * patient under guardianship or curatorship
breath analysis in early stage lung cancer using infrared spectroscopy

Conditions: Lung Cancer; Non Small Cell Lung Cancer

Summary: the aim of this study is to sample and analyze volatile organic compounds (vocs) from lung cancer patients and individuals without lung cancer ("healthy" controls). the breath sample analysis will help investigators describe and identify profiles of vocs found in the breath of patients with lung cancer when compared to normal breath profiles using infrared spectroscopy. this work will help validate early proof of concept results conducted with prototype technology and later stage nsclc breath samples, and inform future breath testing analysis.

globally, lung cancer accounts for the most cancer deaths in both sexes combined. it is believed to develop slowly through progressive accumulation of genetic mutations, hence the disease allows time for diagnosis and curative surgical treatment. five year survival rates for non-small-cell lung carcinoma (nsclc) can range from 57-61% when detected in the early stages of disease. this is compared with a survival rate of approximately 6% once distant metastases are present. however, disease diagnosis typically occurs when it has progressed to an advanced stage when patients present with signs and symptoms. therefore, technologies capable of asymptomatic disease detection will significantly impact lung cancer specific mortality. metabolomic profiling of cancer measures compounds produced as a result of cellular activity including volatile organic compounds (vocs) in exhaled breath. infrared spectroscopy is a proven technique for breath analysis that can measure chemical concentrations in the parts per trillion range for certain vocs. when coupled with machine learning techniques, this has the potential to be a novel approach for disease detection using exhaled breath.

Eligibility criteria:
inclusion criteria lc group: * ≥ 18 years; * able to give informed consent; * eligible for lung cancer screening or lung cancer follow-up testing (biopsy, surgery); * clinical evidence of lung cancer (metastatic or primary), inclusive of those receiving non-curative treatment, has not yet been treated or is not currently on treatment; * no history of or any other active cancer; * able to provide a breath sample; control group: * ≥ 18 years; * able to give informed consent; * eligible for lung cancer screening or lung cancer follow-up testing (biopsy, surgery); * no history of lung cancer or any other active cancer and is eligible for lung cancer screening; * able to provide a breath sample; exclusion criteria * has received or is currently receiving curative treatment and may no longer have lung cancer; * cannot give informed consent;

Keywords: volatile organic compounds breath analysis infrared spectroscopy
cognitive/physical computer-game blended training of elderly: neuroscientific llm studies

Conditions: Mild Cognitive Impairment, So Stated; Mild Dementia; Healthy

Summary: the study involved information and communication technologies (ict) and more specifically computer exercises blended with game activities. it was hypothesized that ict facilitated, game blended cognitive and/or physical exercise improves global cognition when compared to control groups; moreover, these improvements may be manifested by brain activity changes; we explored the impact of potential moderators on combined exercise-induced cognitive benefits, as well as, individual/separate training schemes.

the study was conducted in the thessaloniki (greece), in various centers. it was part of the long lasting memories (llm) project (www.longlastingmemories.eu), which was funded by the european commission (information and communication technologies policy support program (ict-psp) for a three year period (2009-2012). it used a pre-post-test design with the between-participant factor group \[intervention(s) vs. passive and/or active control\]. post-test was conducted within 2 weeks after completion of the exercise period. interventions were carried out in thessaloniki (greece) within day care centers, hospitals, senior care centers, a memory outpatient center, local parishes, and at participants' homes. centers had to provide 8 exercise weeks, with a frequency of at least 2 physical and 3 cognitive exercise sessions per week, resulting in at least 16 physical and 24 cognitive exercise sessions in total. a similar trial was registered with clinical trial registration: clinicaltrials.gov identifier: nct02267499

Eligibility criteria:
inclusion criteria: * no severe cognitive impairment \[mmse ≥ 18\] * fluent language skills * agreement of a medical doctor * time commitment to the test and exercise protocol. exclusion criteria: * concurrent participation in another study * severe physical or psychological disorders which precluded participation in the intervention (i.e., inability to follow instructions) * unrecovered neurological disorders such as stroke, traumatic brain injury, unstable medication within the past three months * severe and uncorrectable vision problems, or hearing aid for less than three months.
a study of hemp hull wfi for ibs diarrhea

Conditions: Irritable Bowel Syndrome-bile Acid Diarrhea

Summary: the purpose of this study is the effect of a study bar, which contains 15 grams of insoluble dietary fiber total sourced from hemp hulls, on intestinal permeability in irritable bowel syndrome (ibs)-bile acid diarrhea individuals.

patients with irritable bowel syndrome-bile acid diarrhea (ibs-bad) have no evidence of significant histologically-evident inflammation or ulceration. the condition is often unrecognized in comparison with natural variations in bowel function in the general population. hemp seeds are a complete source of protein, providing all nine essential amino acids, as well as polyunsaturated fats, especially omega-3 fatty acid, fiber, minerals and vitamins. hemp hulls, the outer shell of the seeds, are typically rich in dietary fiber and phenolics and showed to have a beneficial effect on gut barrier function in vitro. to demonstrate reduced intestinal permeability after 3 weeks of bb01 (20g of bb01, which reflects 15g of insoluble dietary fiber) consumption in a group of 10 patients with ibs-diarrhea with evidence of bile acid diarrhea, a group that has been previously documented to have increased gi permeability.

Eligibility criteria:
inclusion criteria 1. prior diagnosis of bile acid diarrhea as documented by either 1. total bile acid in 48 hour stool excretion of 2337 micromoles per 48 hours, or 2. greater than 1000 micromoles per 48 hours with greater than 4% primary bile acids in stool, or 3. greater than 10% primary bile acid (ca and cdca) in stool 48 hour collection, or 4. serum 7 alpha c4 greater than 52 ng/ml 2. bmi \<40 kg/m2. 3. prior cholecystectomy, appendectomy, and tubal ligation or hysterectomy will all be permissible for participation in the study. 4. participants receiving bile acid sequestrant will not be permitted to continue therapy. and need to stop one week before baseline test. 5. no use of oral antibiotics and nsaids for 2 weeks prior to study treatment exclusion criteria 1. diabetes mellitus (type 1) 2. diabetes mellitus type 2 if taking metformin or glp-1 agonist treatment (exenatide, liraglutide, semaglutide) 3. uncontrolled hypertension (with bp measured \>140/90mmhg in the crtu) 4. bmi ≥40 kg/m2 5. chronic nsaid use (\>1 day/week) 6. use of oral antibiotics and nsaids for 2 weeks prior to and during the entire 21 day study period 7. use of bile acid sequestrant for 1 week prior to and during the entire 21 day study period 8. diagnosis of gastrointestinal diseases that are associated with inflammation such as inflammatory bowel diseases and celiac disease or gastrointestinal infection in the prior 4 weeks; 9. prior intestinal or colonic resection; note prior cholecystectomy, appendectomy, and tubal ligation or hysterectomy will all be permissible for participation in the study 10. participation in highly vigorous exercise such as running \>5 miles per day in week prior to the permeability test
ontogeny of infantile hemangiomas with skin imaging modalities

Conditions: Infantile Hemangiomas

Summary: a combined set of quantitative skin imaging methods will quantitatively describe the natural ontogeny and the response to standard treatments over time in patients with infantile hemangiomas.

infantile hemangiomas (ih) are relatively common benign vascular neoplasms, which appear shortly after birth and grow rapidly in the following weeks and months. the proliferative phase involves a rapidly dividing endothelial cell proliferation. the tumors generally stabilize and then involute over time. they are usually clinically insignificant; however, a small percentage of them can be life threatening secondary to location, associated syndrome, and physical findings such as ulceration. treatment options have included steroids, interferon, vincristine and more recently propranolol. there are few published prospective research studies on the effectiveness of these treatment options. because of several factors, it has been difficult to objectively measure response of these lesions. the purpose is to determine (1) whether multiple quantitative skin imaging modalities can quantitatively describe the clinically relevant features of infantile hemangiomas, including color (red, blue), lightness, size (height, volume), biomechanical properties, temperature and perfusion and (2) the natural ontogeny and response to treatment over time. the treatments are oral propranolol, topical timolol and untreated (observation).

Eligibility criteria:
inclusion criteria: * age ≤ 5 years of age * diagnosis of a cutaneous infantile hemangioma * diagnosis of hemangioma requiring treatment (treatment includes: propranolol or topical timolol) or diagnosis of an infantile hemangioma that will not be treated at the time of enrollment * able to tolerate imaging procedures exclusion criteria: * age \> 5 years * non cutaneous infantile hemangioma * hemangioma on the lip * hemangioma on the eyelid * hemangioma located in areas whereby measurements cannot be made due to equipment limitations * deep hemangioma with no visible skin surface component * congenital hemangioma * no available normal site for study control * other vascular anomaly * not able to tolerate imaging procedures

Keywords: skin imaging image analysis infrared thermography infantile hemangioma three dimensional imaging color imaging and analysis propranolol timolol ontogeny
a clinical study to evaluate the efficacy and safety of hemocoagulase injection

Conditions: Hemoptysis

Summary: this is a multi-centre, randomised, double blind, placebo controlled clinical study which is designed to evaluate the efficacy and safety of hemocoagulase in the treatment of moderate to severe hemoptysis.


Eligibility criteria:
inclusion criteria: * 18-75 years; * hemoptysis \>=100 ml within 24 hours; * bronchiectasis diagnosed by chest high resolution ct; * patient, family or guardian is willing to sign the informed consent form. exclusion criteria: * with severe hepatic or renal insufficiency, alt\>3 uln, creatinine clearance \<30 ml/min or serum creatinine ≥200 µmol/l or ≥2.5 mg/dl; * uncontrollable hypertension (sbp\>180mmhg or dbp\>110mmhg) or hypotension shock (sbp\<90 mmhg) at randomization; * history of thrombosis, patients who have undergone thrombosis, or who have severe hematologic diseases; * patient with bleeding caused by dic or vascular disease; * patient with coagulation dysfunction 1. inr\>2 2. patient with abnormal coagulation function or other bleeding disease (including clinical congenital bleeding disorders, such as von willebrand disease or acquired hemophilia; hemorrhagic disease; and significant unexplained hemorrhagic disease) 3. platelet count \<100×109 /l; * known allergic to aspirin, clopidogrel, heparin, snake venom blood clotting enzyme, or any component in the study drug allergy or allergic constitution; * women who are pregnant or lactating and women of child-bearing agewho do not take reliable contraceptive measures; * patients who are or are planning to participate in other clinical trials during the study period; * within 72 hours before using the following products including hemocoagulase for injection (邦亭®), injection spearhead haemocoagulase (巴曲亭®), haemocoagulase agkistrodon for injection (苏灵®), hemocoagulase atrox for injection (立止血®), leaf pigment or other hemostatic agents; * life expectancy of less than 3 months; * any other patients who have been judged unfit to participate in this clinical study, including those who are unable or unwilling to comply with the protocol requirements; * patients who had participated in other clinical studies within three months prior to the study.
silicone gel to improve scar in microtia patients

Conditions: Microtia; Scar

Summary: effort to reduce post-surgical scar is especially important for microtia patients. even the scar lies posterior to ear auricle, but hypertrophic scar contracture may limit the ear auricle projection. if the scar is hypertrophic and conspicuous, this stigmata will accompanies the child for many years.the main objective aim of this study is to examine whether post-operative use of silicone gel can improve scar formation for microtia reconstruction scars.

background: a scar represents dermal fibrous replacement tissue and results from a wound that has healed by resolution rather than regeneration. undesirable scars, such as hypertrophic or keloid scars, occur most frequently over the anterior chest, shoulders, scapular area, lower abdomen and suprapubic region. many of the investigators' microtia patients complained postsurgical hypertrophic scar. the incidence of hypertrophic scars after microtia reconstruction could be 6.29%. effort to reduce post-surgical scar is especially important for microtia patients. even the scar lies posterior to ear auricle, but hypertrophic scar contracture may limit the ear auricle projection. if the scar is hypertrophic and conspicuous, this stigmata will accompanies the child for many years. the micropore tapes is very useful for facial scars. however, because of retroauricular contour and hairline, micropore tapes is difficult to retained over it place. self-dry silicone gel is effective in both treatment and prevention of hypertrophic scar. it is consider first line for hypertrophic prevention in last update of facial scar care. the main objective aim of this study is to examine whether post-operative use of silicone gel can improve scar formation for microtia reconstruction scars. patients and methods: this is a prospective randomize clinical trial primarily designed to compare the scarring after second stage of microtia repair with post-operative use of self-drying silicone gel. the control group did not use self-drying silicone gel for their scar care. the study group will receive application of self-dry silicone gel (dermatix ultra gel - invida, hanson medical inc, usa) twice a day. six months after surgery, vancouver scar sale and visual analogue scale will be used for subjective scar measurement. standard craniofacial photograph will be taken at the same time. a surgical ruler will be placed underneath the op wound. the scar width will be measured using with commercial software.

Eligibility criteria:
inclusion criteria: * patients with microtia. * written informed consent given by parent/guardian. exclusion criteria: * combined other craniofacial anomalies * without permission of parent/guardian, without signed informed consent by parent/guardian.
the treatment of coronary de-novo lesions with the elutax paclitaxel-eluting balloon alone, a pilot study

Conditions: Stable Angina; Coronary Stenosis

Summary: a randomised open-label pilot study to assess the safety and efficacy of treatment with a drug eluting balloon alone in coronary de novo lesions). elective patients requiring pci to coronary de novo lesions in vessels 2.5 mm - 4.0 mm.


Eligibility criteria:
inclusion criteria: * patient ≥ 18years old * stable angina symptoms * elective treatment to coronary lesion * reference vessel diameters of ≥ 2.5mm and ≤ 4.0 mm on visual inspection exclusion criteria: * left main stem lesion * bifurcation lesions * acute coronary syndrome (uap, nstemi, stemi) * cardiogenic shock * chronic total occlusion * additional lesions requiring pci * platelet count ≤ 50 x 109/mm3 * left ventricular ejection fraction ≤ 30% * patient life expectancy less than 12 months * known allergies to aspirin, clopidogrel, prasugrel, heparin, stainless steel, intravenous contrast (severe), or paclitaxel * participation in another investigational drug or device study * patient unable to give informed consent
a study evaluating pf-03084014 in patients with advanced breast cancer with or without notch alterations

Conditions: Triple Negative Breast Neoplasms

Summary: this study is designed to evaluate the preliminary anti-tumor activity and tolerability of pf-03084014 when administered as a single agent in the treatment of patients with advanced triple receptor-negative breast cancer (mtnbc) harboring genomic alterations in notch receptors (na+), and in a smaller subset of mtnbc patients whose tumor tests negative for genomic alterations in notch receptors (na-)


Eligibility criteria:
inclusion criteria: * histological or cytological diagnosis of triple negative breast cancer (tnbc) with evidence of a) metastatic or b) locally recurrent advanced disease that is not amenable to resection or radiotherapy with curative intent. * availability of an original diagnostic tumor tissue or the most recent metastatic tumor biopsies (archival biopsy or de novo biopsy) and a peripheral blood sample for notch receptors genomic profiling exclusion criteria: * known brain metastases. * prior treatment with gamma secretase inhibitor or other notch signaling inhibitor.

Keywords: pf-03084014 notch alterations